SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), a $271 million market cap player in the health and wellness sector with impressive 79% gross profit margins, today announced the successful ...
About one in eight adults in the United States has tried or currently uses a GLP-1 medication, and a quarter of those users cite weight loss as their main goal. But weight loss doesn't discriminate ...
There's a growing body of evidence that gold nanoparticles can offer significant, targeted weight loss that focuses on fat ...
Ozempic and other GLP-1 agonists are helping millions with weight loss but concerns grow over their long-term effects. Recent ...
A brand new candidate for weight-loss treatment is on the table, with scientists uncovering for the first time how a hormone ...
DTC Telehealth Platforms - Arrangements involving telemedicine and direct-to-consumer (“DTC”) business services are expected to be a source ...
After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...
Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight ...
With the recent surge in popularity of weight loss drugs like Ozempic, altogether called GLP-1s, there has been renewed scientific interest in understanding how our bodies regulate muscle growth. Salk ...
HCR-188, a clinic-ready antibody, entering first-in-human clinical studies with top-line data anticipated in the second half ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback